Xiamenmycin A is an antifibrotic leading compound with a benzopyran skeleton\nthat is isolated from mangrove-derived Streptomyces xiamenensis. As a promising small\nmolecule for fibrotic diseases, less information is known about its metabolic characteristics\nin vivo. In this study, the time-course of xiamenmycin A in mouse plasma was investigated\nby relative quantification. After two types of administration of xiamenmycin A at a single\ndose of 10 mg/kg, the plasma concentrations were measured quantitatively by LC-MS/MS.\nThe dynamic changes in the xiamenmycin A concentration showed rapid absorption and\nquick elimination in plasma post-administration. Four metabolites (M1ââ?¬â??M4) were identified\nin blood by UPLC-QTOF-MS, and xiamenmycin B (M3) is the principal metabolite in vivo,\nas verified by comparison of the authentic standard sample. The structures of other\nmetabolites were identified based on the characteristics of their MS and MS/MS data. The\nnewly identified metabolites are useful for understanding the metabolism of xiamenmycin A\nin vivo, aiming at the development of an anti-fibrotic drug candidate for the therapeutic\ntreatment of excessive fibrotic diseases.
Loading....